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Cross-talk between Gi- and Gq-linked G-protein-coupled
receptors yields synergistic Ca2 responses in a variety of cell
types. Prior studies have shown that synergistic Ca2 re-
sponses frommacrophage G-protein-coupled receptors are
primarily dependent on phospholipase C3 (PLC3), with a
possible contribution of PLC2, whereas signaling through
PLC4 interferes with synergy. We here show that synergy can
be induced by the combination of G and Gq activation of a
single PLC isoform. Synergy was absent in macrophages lack-
ing both PLC2 and PLC3, but it was fully reconstituted fol-
lowing transduction with PLC3 alone. Mechanisms of PLC-
mediated synergy were further explored in NIH-3T3 cells,
which express little if any PLC2. RNAi-mediated knockdown
of endogenous PLCs demonstrated that synergy in these cells
was dependent on PLC3, but PLC1 and PLC4 did not con-
tribute, and overexpression of either isoform inhibited Ca2
synergy. When synergy was blocked by RNAi of endogenous
PLC3, it could be reconstituted by expression of either hu-
man PLC3 or mouse PLC2. In contrast, it could not be re-
constituted by human PLC3 with a mutation of the Y box,
which disrupted activation by G, and it was only partially
restored by human PLC3 with a mutation of the C terminus,
which partly disrupted activation by Gq. Thus, both G and
Gq contribute to activation of PLC3 in cells for Ca2 syn-
ergy. We conclude that Ca2 synergy between Gi-coupled
and Gq-coupled receptors requires the direct action of both
G and Gq on PLC and is mediated primarily by PLC3,
although PLC2 is also competent.
Phosphoinositide-specific phospholipase C (PLC)5-depen-
dent Ca2 responses are stimulated by several types of cell
surface receptors, including members of the GPCR family.
Gq-linked GPCRs stimulate Ca2 responses in most cells,
whereas Gi-linked receptor stimulation of Ca2 release is
variably seen, and the factors that determine this variation are
not well understood (1–3). Simultaneous activation of Gi-
and Gq-linked GPCRs has revealed pathway cross-talk, re-
sulting in synergistic Ca2 responses in a variety of primary
and cultured cell types (4–10). Proposed mechanisms have
included effects on receptor availability, changes in G-protein
turnover, increased availability of the PLC substrate phos-
phatidylinositol 4,5-diphosphate, increased sensitivity of in-
tracellular stores to inositol 1,4,5-trisphosphate, and en-
hanced linkage of intracellular Ca2 release to Ca2 influx (5).
From these disparate results, it is clear that the mechanisms
for Ca2 synergy may vary between systems and contexts.
We recently demonstrated that Gi- and Gq-coupled
GPCRs synergize in stimulating a rise in [Ca2]i in macro-
phages (11). Synergy required simultaneous receptor activa-
tion, and it affected both the initial release of Ca2 from in-
tracellular stores and the sustained elevation in Ca2 levels.
Similar to synergy in other cell types, synergy in macrophages
occurred at the level of inositol 1,4,5-trisphosphate produc-
tion (10, 12–16). Although macrophages express multiple
PLC isoforms, these were used selectively in Ca2 signaling
and synergy. In particular, PLC3 mediated most of the syn-
ergy, with a possible minor contribution by PLC2, whereas
PLC4 inhibited synergy (11). In contrast to the synergy in
PLC activation, phosphatidylinositol 3-kinase activation was
inhibited by the same signal interactions, demonstrating di-
vergence in signaling effects on effector pathways down-
stream of the GPCRs.
Previous biochemical investigations of PLC isoforms have
demonstrated differential sensitivity to activation by G-pro-
tein subunits; whereas PLC2 and PLC3 bind to and are
activated by both G and Gq, PLC4 is effectively activated
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only by Gq (17–20). At the receptor level, Gi-linked GPCRs
activate PLC through binding of G alone, whereas signal-
ing through Gq-linked GPCRs may activate PLC through
both G and Gq. Thus, synergy in Ca2 signaling could
involve effects of both G and Gq on PLC2 or PLC3.
Alternatively, it could involve activation of PLC by only one
of the two G-proteins. For example, synergy could involve
only G interactions between receptors, especially if differ-
ent G subunits were used by each receptor (21). Synergy
could also be mediated solely by Gq, with increased G
levels serving to enhance the recycling of GTP-Gq, but this is
unlikely because this effect should enhance the activity of
PLC4, and it does not (11).
In the current studies, we further examined the mechanis-
tic requirements for PLC-mediated Ca2 synergy responses.
Studies of PLC-deficient primary macrophages revealed that
only one PLC isoform is required for synergy, either PLC3
or, less potently, PLC2.
To dissect the molecular mechanisms involved in synergy,
we employed a cellular system with a greater efficiency of
transfection and higher throughput than primary BMDMs,
mouse NIH-3T3 cells expressing C5aR. This model permits
Gi-mediated signaling in response to C5a together with
Gq-mediated signaling through endogenous P2Y receptors
in response to UDP or UTP.
Studies of the NIH-3T3 model supported and extended the
observations in macrophages. They demonstrated a robust
synergistic Ca2 response to C5a and UDP and demonstrated
that synergy is dependent on endogenous PLC3. In contrast,
PLC1 or PLC4 inhibited synergy, and inhibition by PLC4
required its C-terminal, Gq binding site. Following knock-
down of PLC3 by RNAi, synergy could be restored by ex-
pression of either human PLC3 (hPLC3) or mouse PLC2
(mPLC2), which is not expressed natively in these cells.
Mutational analyses of hPLC3 revealed that both G and
Gq binding sites are necessary for full synergistic activation
of PLC3 in 3T3 cells, confirming the requirement for both
activators of PLC3 in intact cells. We conclude that synergy
between G and Gq occurs directly at the level of PLC3.
EXPERIMENTAL PROCEDURES
Reagents—UDP, UTP, LPA, platelet-activating factor, human
C5a, spiradoline, and FITC-dextran were from Sigma-Aldrich.
S1P was fromAvanti Polar Lipids. Mouse IgG2a was from BD
Pharmaceuticals. F(ab)2 fragments of goat anti-mouse IgG were
from Jackson Immunoresearch Inc. Anti-PLC3 clone B521 was
from Paul Sternweis (University of Texas Southwestern) (17).
Anti-phospho-Akt and anti-phospho-ERKwere fromCell Sig-
naling Technologies. Fura2 was fromMolecular Probes. Ionomy-
cin, thapsigargin, and pertussis toxin (PTx) were fromCalbio-
chem. Detailed protocols for reagents, procedures, and solutions
are provided upon request and are referenced according to pro-
tocol number (e.g. PP00000172).
Culture of NIH-3T3 Cells—NIH-3T3 cells were maintained
in DMEM with 10% FBS and 2 mM L-glutamine (PS00000663).
Mice and Culture of BMDMs—PLC3-deficient mice were
on a C57BL/6 background after 7 generations of backcrossing
(22), and PLC2-deficient mice were on 129SvEV background
(23). For mice doubly deficient in PLC3 and PLC2,
PLC2/mice were crossed twice to C57BL/6 mice and a
PLC2/mouse was crossed to PLC3/mice. Mice were
bred and housed under approved animal protocols. To obtain
BMDMs, femurs and tibias were removed from sex- and age-
matched mice (4–20 weeks of age, matched4 weeks)
(PP00000172). Briefly, marrow was flushed from bones, eryth-
rocytes were lysed, and the white cells were seeded in non-
tissue culture Petri dishes for differentiation and selection of
macrophages by growth and adhesion. After 6 days, over 99%
of the surviving cells were macrophages, as assessed by ex-
pression of CD11b/M integrin and CD115/c-Fms/MCSF
receptor, and these cells were maintained in culture for up to
35 days. Cells were cultured overnight in tissue culture plates
prior to use in assays.
Cell Transduction with siRNA, Plasmid Expression Con-
structs, and Retroviruses—For RNAi, 3T3 cells were plated at
1.25 105 cells/well in 6-well plates 24 h prior to transfec-
tion. Lipofectamine 2000 was used to deliver siRNA oligonu-
cleotides at a final concentration of 100 nM. Media were
changed 24 h post-transfection, and cells were plated for assay
48 h post-transfection (PP00000262). Bioassays and sampling
for mRNA and protein expression level assessments were per-
formed 72 h post-transfection. Knockdown efficiency of
mRNA was quantified by quantitative RT-PCR, and proteins
were quantified by Western blotting where antibodies were
available.
The cDNA for human C5aR, with an N-terminal FLAG
epitope, was generously provided by Henry Bourne (Univer-
sity of California San Francisco) and was transferred to
pcDNA4zeo (Invitrogen). The cDNA for the mutant -opioid
receptor (RASSL form Ro2 (24)) was generously provided by
Bruce Conklin (University of California San Francisco) and
was transferred to pMXpie (25). Murine, human, and bovine
PLC-YFP fusion proteins and mutant constructs were pre-
pared by using previously described cloning methods and
constructs (26). The domain structure of PLC is shown in
Fig. 1, where previously demonstrated binding sites for G
and Gq are indicated (reviewed in Ref. 27). Residues in the
Y-box and the C-terminal domains of either PLC3 or PLC4
were targeted for mutation to interfere with G or Gq
binding, respectively. Briefly, hPLC3 and bovine PLC4
cDNAs were cloned in gateway entry vectors, and site-di-
rected mutagenesis was directed at putative G-protein inter-
action sites by using QuikChange (Stratagene), according to
the method of the manufacturer. For both hPLC3 and bo-
vine PLC4, four amino acids that are predicted to contribute
to Gq interaction at the C terminus (hPLC3: Lys965, Arg969,
Asp1074, and Arg1089; bovine PLC4: Lys942, Lys946, Ser1068,
and Arg1083) were mutated to alanine (28, 29). For hPLC3,
three amino acids that are predicted to contribute to G
interaction (Glu622, Thr623, and Lys624) were also mutated to
alanine (30, 31). For mPLC2, a stop codon was introduced
after amino acid 840. N-terminal YFP tags were added to
PLC sequences by Gateway (Invitrogen) recombination to
either pDS_EF1-YFP-XB for mammalian plasmid expression
or to pDS-FBneo YFP-X for retroviral expression (AfCS plas-
mids, available through ATCC). Control constructs were ei-
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ther empty vector, YFP alone, or YFP-FLAG versions. For in
vitro assessment of hPLC3 mutants, the recombinant pro-
teins were produced via the baculovirus expression vector
system. His tags were added to the C termini, the sequences
were transferred to pFastBac1 vectors, SF9 cells were trans-
fected, and the proteins were purified from cell lysates by one-
step affinity chromatography on Ni2-nitrilotriacetic acid-
agarose (Qiagen) (28).
3T3 cells were transfected with stable mammalian expres-
sion vectors by using Lipofectamine 2000. Amphotropic or
ecotropic retroviruses were produced by using the Phoenix
(32) or PlatE (33) packaging lines, respectively, with pMXpie
or pFB-neo (Stratagene) vectors. 3T3 cells were selected and
maintained in 100 g/ml zeocin, 400 g/ml G418, or 1 g/ml
puromycin, either alone or in combination as appropriate.
Where required, fluorescent cell populations were enriched
by cell sorting by using a FACSAria (BD Biosciences). Expres-
sion levels were evaluated by Western blotting using anti-
PLC3. The molecular weight difference between endoge-
nous PLC3 and transduced YFP-PLC3 allowed
differentiation of bands corresponding to each form.
Primary BMDMs were transduced by using retroviruses.
Proliferating myeloid progenitor cells were infected on two
consecutive days, beginning within 2 days of isolation from
mouse femurs. Overnight infections with retrovirus-contain-
ing supernatants included Polybrene at 8 g/ml. After expan-
sion, transduced macrophages were harvested and replated on
tissue culture plastic or poly-L-lysine-coated glass chamber
slides 24 h prior to assay.
In Vitro PLC Activity Assays—PLC activity was measured
by hydrolysis of [3H]phosphatidylinositol 4,5-diphosphate as
described previously (28, 34). Briefly, the reactions of purified
PLC enzymes, G-protein subunits, and [3H]phosphatidyl-
inositol 4,5-diphosphate (added as mixed phospholipid vesi-
cles) were allowed to proceed at 30 °C for 10 min. Ca2 was
maintained at 0.2 M. Gq-stimulated activity was measured
in the presence of (0.2 or) 2 nM Gq (EC50) that had been
previously activated by incubation with GTPS. G-stimu-
lated activity was measured in the presence of 30 nM G.
Population Calcium Assays—Ca2 responses were mea-
sured by monitoring the fluorescence of Fura-2-loaded cells
(PP00000211). Base-line readings were collected for 30–40 s
prior to stimulation with ligands. Calibration steps included
the additions of a Ca2-minimizing solution (PS00000607)
and Fura-2 Ca2-saturating solution (PS00000608) at the end
of each recording to allow calculation of [Ca2]i values ac-
cording to the method of Grynkiewicz et al. (52), assuming a
cytoplasmic kD value of 250 nM for Fura-2. Ca2 signals dur-
ing the response period were quantified by features as indi-
cated, including the peak offset response (difference between
base-line Ca2 level and the maximal Ca2 level observed,
reported in nM) and an integrated response (integrated Ca2
level above the average base line over the indicated time pe-
riod, reported in nM s).
Single-cell Calcium Assays—Cells were plated in chambered
coverglasses (Nunc, 8 wells/coverglass), cultured overnight, and
loaded with Fura-2/AM as described above. Videomicroscopy
was performed by using a Nikon TE-300 fluorescencemicro-
scope equipped with a Photometrics HQ2 camera, 37 °C stage
incubator (Bionomics), xenon lamp (Sutter), and filter/shutter/
dichroic controllers (Sutter and Conix). SimplePCI software was
used to control collection parameters and to extract fluorescence
intensity data for individual cells. Intracellular [Ca2]iwas esti-
mated as described for population assays.
Statistical Analyses—The error bars in graphs depict the
S.E. The statistical significance of each comparison was evalu-
ated by performing Student’s t test or a one-way analysis of
variance followed by Dunnett’s test or individual t tests (with
Bonferroni correction). A p value of0.05 was considered
significant.
RESULTS
Macrophages Deficient in Both PLC2 and PLC3 Have No
Synergistic Ca2 Response to C5a and UDP—Synergy in Ca2
signaling in macrophages between C5a, acting on the Gi-
coupled C5aR, and UDP, acting on Gq-coupled P2Y recep-
tors, was previously found to be primarily dependent on expres-
sion of PLC3, but some synergy remained in PLC3-deficient
cells (11). Because PLC4 appears to have an inhibitory role and
PLC1 is not expressed inmacrophages, the residual Ca2 syn-
ergy in PLC3-deficient macrophages was thought to depend on
PLC2 (11). To test this hypothesis, we examined Ca2 synergy
in mousemacrophages deficient in both PLC2 and PLC3
(PLC2/3/) in comparison withmacrophages deficient in
PLC3 alone (PLC3/). In the absence of both PLC2 and
PLC3, BMDMs (which still expressed PLC4) lost the residual
synergy that was apparent in macrophages deficient in PLC3
alone (Fig. 2,A–C). Thus, although synergy in macrophages is
FIGURE 1. Schematic of PLC structure and design of G-protein binding
site mutants. The theoretical PLC structural domain organization (NCBI) is
shown along with sites of modification as described under “Experimental
Procedures.” YFP was added as an N-terminal fusion protein, and point mu-
tations targeting G and Gq binding sites, based on homology to PLC1,
were created as X3 Ala mutations (*). The arrows indicate the location of
amino acids mutated, and the numbers indicate their position relative to the
N terminus of hPLC3. The species of isoform used is indicated as human
(h) and bovine (b). Also used but not shown are YFP-mPLC1, -2, -3, and -4
without mutation and mPLCb2 truncated at amino acid 840.
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primarily dependent on PLC3, PLC2 is capable of supporting
synergy.
The Ca2 response to UDP alone in PLC2/3/macro-
phages differed little from the response by macrophages defi-
cient in PLC3 alone (Fig. 2D), presumably reflecting activa-
tion of PLC4 by Gq, but the Ca2 response to C5a alone
was diminished in PLC2/3/ BMDMs compared with
macrophages deficient in PLC3 alone, indicating a contribu-
tion from PLC2.
Reconstitution of PLC2/3-deficient BMDMs with PLC3
Alone Restores Synergy—The capacity of PLC3 alone to
support Ca2 synergy was evaluated by reconstituting wild
type or PLC2/3-deficient BMDMs with PLC3 coupled to
YFP or, as a control, with FLAG peptide coupled to YPF.
Introduction of wild-type PLC3 increased single-ligand
responses to both C5a and UDP, and it restored synergy to
normal levels (Fig. 2E and supplemental Fig. S1). Thus,
synergy can be supported by either PLC2 or PLC3
alone.
In these studies, transduction of PLC into BMDMs was
inefficient, requiring the study of large numbers of cells to
obtain statistically valid results. Therefore, for further studies
of the role of PLC isoforms in synergy, we moved to the
study of NIH-3T3 cells stably expressing C5aR, beginning
FIGURE 2. Ca2 synergy in BMDMs depends primarily on PLC3 with a small contribution by PLC2. BMDMs from WT, PLC3-deficient
(PLC3/), or double PLC2- and PLC3-deficient (PLC2/3/) mice were assayed for their ability to reflect synergistic responses to C5a plus UDP.
Intracellular Ca2 responses were measured in Fura-2-loaded cells stimulated with C5a (0.75 nM), UDP (500 nM), or both ligands. Responses from WT
(A) and PLC2/3/ (B) BMDMs are indicated by the line graphs, in which each line represents the average of 3–4 individual wells/assay. Data shown
are from representative experiments of n  18 with similar results. C, summary of synergy responses from WT, PLC3/, and PLC2/3/ BMDMs.
The predicted additive responses for dual-ligand stimulation were calculated for each assay from the measured single-ligand responses, and a syn-
ergy ratio was determined as the ratio of the observed/predicted additive dual-ligand responses, using the peak offset feature. Values shown are
mean  S.E. from n  18–20 replicate assays/condition. D and E, single-ligand Ca2 responses in PLC-deficient BMDMs. D, wild-type, PLC3/,
and PLC2/3/ cells were stimulated with C5a (10 nM) or UDP (10 M), and the Ca2 responses were measured. Shown are the results for peak off-
set responses. Results are mean  S.E. from n  3 assays. *, p  0.05. E, expression of mPLC3 in PLC2/3/ BMDMs restores synergistic Ca2 re-
sponses to levels observed in WT BMDMs. Single-cell Ca2 assays were performed on WT or PLC2/3/ BMDMs transduced with retrovirus encod-
ing YFP-FLAG or YFP-mPLC3. Cells were stimulated with C5a (0.75 nM), UDP (500 nM), or C5a  UDP, and the Ca2 responses were measured by
integration over 2.25 min. Responses by transduced cells were measured in multiple assays of each of three independent batches of infected BM-
DMs. Values shown are mean  S.E. from n  5–6 samples per condition. *, p  0.05.
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with validation of these cells as a model for synergy in Ca2
signaling between Gi- and Gq-coupled receptors.
NIH-3T3 Cells Demonstrate Robust Synergy in Ca2 Signal-
ing in Response to Endogenous Purinergic Receptors (P2YRs)
and a Stably Transfected C5a Receptor (C5aR)—Mechanistic
studies of the signaling interaction between C5a and UDP or
UTP GPCRs at the level of PLC activation were performed
in mouse NIH-3T3 cells expressing a stably transfected hu-
man C5aR and endogenous P2YRs. Robust synergy between
C5a and either UDP (Fig. 3A) or UTP (Fig. 3B) was observed,
both in the initial peak and in sustained levels of [Ca2]i. C5a
or UDP alone generated low or undetectable Ca2 responses,
even at concentrations up to 100 M (Fig. 3B and supplemen-
tal Figs. S2 and S3). Substituting UTP for UDP, however, con-
sistently gave a detectable response by itself, and this was ele-
vated by C5a to levels 2–4 times the predicted additive value
(Fig. 3C). Of note, C5a increased Ca2 responses to UTP even
when UTP was used at maximal concentrations, evidence that
C5a recruits signaling pathways that are not utilized by UTP.
To confirm that NIH-3T3 cells serve as an adequate model
for synergy in Ca2 signaling between Gi- and Gq-linked
GPCRs, we evaluated synergy by a number of alternate recep-
tor pairings with or without inhibition of Gi signaling by
PTx. As expected, the C5a and synergistic responses to UTP
C5a were sensitive to PTx (supplemental Fig. S4), whereas the
responses to UTP were not (supplemental Fig. S5A), as seen
previously in BMDMs (11). Endogenous LPA and S1P recep-
tors generated PTx-sensitive Ca2 responses (supplemental
Fig. S5A), as did a transfected modified -opioid GPCR, Ro2
(24), which signals solely through Gi in response to spirado-
line (supplemental Figs. S5C and S6). A screen of dual-ligand
Ca2 responses showed that pairs of receptors with heterolo-
gous couplings to Gi and Gq showed synergy, whereas ho-
mologous couplings did not (supplemental Fig. S5, B and D;
summarized in supplemental Table S1). Thus, Ca2 synergy
in NIH-3T3 cells reflects Gq/Gi GPCR cross-talk, as it does
in macrophages and several other cell types.
Ca2 Synergy in NIH-3T3 Cells Depends on Endogenous
PLC3—We next sought to determine the contribution of
different PLC isoforms to Ca2 signaling in NIH-3T3 cells.
By quantitative RT-PCR, NIH-3T3 cells expressed relatively
high levels of PLC1 and PLC3 transcripts but lower levels
of PLC4 and little or no PLC2 (Fig. 4). Expression of each
isoform was selectively reduced by RNAi, which reduced tran-
scripts for PLC1, PLC3, and PLC4 by 60–80% (supple-
mental Fig. S7A). Only the knockdown of PLC3 significantly
reduced the Ca2 synergy response (Fig. 5). Knockdown of
PLC2 had no effect, but this isoform is not significantly ex-
pressed in NIH-3T3 cells, so this may be viewed as an addi-
FIGURE 3. C5a in combination with UTP or UDP yields synergistic Ca2
responses in NIH-3T3 cells. Intracellular Ca2 levels were calculated for
Fura-2-loaded NIH-3T3 cells stably expressing the human C5aR in kinetic
assays in 96-well plates. After 40 s base-line readings, cells were stimulated
with UDP (100 M), UTP (100 M), C5a (10 nM), or a combination of these
ligands, and responses were monitored for 2.5 min. Shown are a combina-
tion of C5a UDP (A) and a combination of C5a UTP (B). Each line in the
graphs represents the average of 4–5 individual wells/assay, and the error
bars (S.E.) are shown for the dual-ligand line in each graph. Synergy was
evaluated by comparing the experimentally observed dual-ligand re-
sponses to the predicted additive responses of the individual ligands. C, the
responses were quantified by using peak offset measurements, the differ-
ence from base line to observed peak. The dual-ligand responses were com-
pared with the predicted additive responses (sum of single-ligand re-
sponses) and a synergy ratio calculated as observed/predicted additive
peak offsets. For the C5a UTP experiment shown, the synergy ratio was 2,
but the predicted additive level for C5a UDP was too low for reliable esti-
mation of the synergy ratio. Data shown are from a representative assay of
n 7 with similar results.
FIGURE 4. Expression of PLC isoforms in NIH-3T3 cells.Quantitative
RT-PCR was used to measure PLC isoformmRNA levels. mRNA levels were
compared with -actin in each assay and normalized to PLC1 levels. Data
are mean S.E. (error bars) from three assays.
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tional negative control. Knockdown of PLC1 or PLC4 in-
creased synergy, but this change did not reach statistical
significance for either isoform. These results are similar to our
results in genetically deficient BMDMs, where the absence of
PLC3 reduced synergy, whereas the absence of PLC4 en-
hanced synergy (PLC1 is the closest isoform to PLC4 bio-
chemically (27)). Hence, our results in both BMDMs and
NIH-3T3 cells indicate that PLC3 contributes to synergy in
Ca2 signaling, whereas PLC4 or PLC1 do not and instead
inhibit synergy. Knockdown of single PLC isoforms did not
significantly alter single-ligand Ca2 responses; responses to
C5a were too low to identify changes, whereas UTP responses
were not affected by knockdown of PLC2 or PLC3 and only
slightly affected by knockdown of PLC1. Presumably, the
loss of individual PLC isoforms following RNAi is compen-
sated by signaling through others, all of which can bind Gq.
Overexpression of PLC Isoforms Selectively Enhances or
Reduces Ca2 Signaling—To further examine the selectivity
of PLC isoforms in contributing to Ca2 synergy, we overex-
pressed YFP-tagged PLC isoforms in NIH-3T3 cells. By flow
cytometry, the PLC isoforms were expressed at comparable
levels (supplemental Fig. S7, B and C). By Western blotting,
PLC3 levels were 2.7 0.2-fold above levels of endogenous
PLC3 (data not shown). Ca2 responses were compared
with responses by cells transfected with YFP-tagged FLAG
epitope (YFP-FLAG). Overexpression of PLC3 had no signif-
icant effect on any single-ligand responses, perhaps because
endogenous levels of this PLC isoform are already high.
Overexpression of PLC2, however, markedly enhanced the
response to C5a, although it did not alter signaling to UTP,
LPA, or S1P. The capacity of PLC2 to augment C5a signal-
ing following overexpression in 3T3 cells, whereas overex-
pression of PLC3 did not, suggests that PLC2 may differ
qualitatively from PLC3 in its activation by C5a. Overex-
pression of PLC1 or PLC4 augmented Gq-coupled UTP
responses (Fig. 6A), but it inhibited the Gi-coupled re-
sponses by C5a, LPA, and S1P, perhaps reflecting differences
in PLC isoform activation by Gq versus G subunits (17,
18, 20). Overall, the results of PLC overexpression suggest
that Ca2 responses to C5a may be inhibited by PLC iso-
forms that are less sensitive to G (PLC1 and PLC4), but
they are enhanced by isoforms that are activated by G
(PLC2). Synergy in response to dual ligands also differed
FIGURE 5. Knockdown of PLC3 in NIH-3T3 cells reduces C5aUTP
Ca2 synergy. siRNA-mediated knockdown of PLC isoforms in NIH-3T3-
C5aR cells preceded assays of C5a UTP Ca2 synergy. PLC isoform-spe-
cific siRNA versus LacZ control siRNA were applied to cells 72 h prior to as-
say. A, cells were stimulated with UTP (100 M), C5a (10 nM) or UTP C5a.
Integrated measures of synergy were normalized to responses of control
cells in each assay (dotted line, representing an average synergy ratio of 3.5).
B, single-ligand responses following PLC isoform-specific RNAi. Peak offset
values were calculated for each response. Results are mean S.E. (error
bars) from n 3–5 assays/condition from independent rounds of RNAi. *,
p 0.05.
FIGURE 6.Overexpression of PLC isoforms in NIH-3T3 cells perturbs
single- and dual-ligand responses. NIH-3T3 cells stably expressing YFP-
PLC isoforms or YFP control protein were assayed for Ca2 responses to
individual ligands (A) and C5a UTP dual ligand (B). A, single-ligand con-
centrations were 100 M UTP, 10 nM C5a, 500 nM LPA, and 500 nM S1P. Re-
sponses were normalized to YFP control lines using the peak offset mea-
sures of the responses. B, synergy between C5a (10 nM) and UTP (100 M)
was measured using the integrated responses and normalized to responses
of control cells in each assay (dotted line, representing an average synergy
ratio of 2.7). Values shown are mean S.E. (error bars) from n 3 assays. *,
p 0.05.
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between either PLC1 or PLC4 relative to PLC2 or PLC3.
Overexpression of PLC1 or PLC4 inhibited synergy follow-
ing stimulation with C5a plus UTP (Fig. 6B), but this inhibi-
tion was lost with mutation of Gq-binding domain of PLC4
(supplemental Fig. S7D). In contrast, overexpression of
PLC2 or PLC3 did not alter synergy; the synergy ratio was
maintained and was not further increased by overexpression
of PLC2 or PLC3. As noted above, signaling by C5a alone
rose substantially following overexpression of PLC2, and so
did dual-ligand signaling by C5a plus UTP, but the synergy
ratio was the same as in YFP-transfected cells, suggesting that
PLC2 overexpression augments the magnitude of synergy
responses in parallel with its augmentation of signaling by
C5a alone. Thus, results from overexpression of PLC iso-
forms are consistent with the results from the knockdown
experiments in supporting an inhibitory effect of PLC1 or
PLC4 on Ca2 response synergy, in contrast with depend-
ence for synergy on PLC3. Although PLC2 is normally not
found in NIH-3T3 cells, it appears capable of contributing to
synergy, as it can in BMDMs (although its contribution to
synergy in BMDMs is low).
Reconstitution of PLC3 Expression Restores Ca2 Synergy
Lost with PLC3 RNAi—To further validate the requirement
for PLC3 expression for Ca2 synergy, we combined knock-
down of endogenous murine PLC3 in NIH-3T3 cells by
RNAi with restoration of PLC3 expression by transfection of
human PLC3. The RNAi sequence targeted mPLC3 but
not hPLC3. RNAi reduced mPLC3 mRNA by 74 7%, as
assessed by species-specific quantitative RT-PCR, and it re-
duced mPLC3 protein by 50–80% (supplemental Fig. S8), as
assessed by Western blotting. In accord with this, RNAi re-
duced Ca2 synergy by 60–70% (Fig. 7, A, B, and E). Expres-
sion of hPLC3 reversed the loss of synergy following knock-
down of mPLC3 by RNAi (Fig. 7, C–E), supporting the
conclusion that the loss of synergy following RNAi of PLC3
reflects knockdown of PLC3 expression. The restoration of
synergy by transfected hPLC3 was not due to negation of the
RNAi by hPLC3 (e.g. by binding siRNA) because mPLC3 re-
mained suppressed (supplemental Fig. S8B). Indeed, attempted
overexpression of transcripts for mPLC3 instead of hPLC3
failed to restore synergy (supplemental Fig. S9C), because knock-
down of mPLC3 persisted (supplemental Fig. S8B). Synergy
FIGURE 7. Expression of human PLC3 can compensate for knockdown of endogenous murine PLC3. NIH-3T3 cells were stably transfected with YFP
(A and B) or YFP-hPLC3 (C and D) and subjected to RNAi using murine-specific anti-PLC3 (B and D) or LacZ control (A and C) siRNA. Ca2 assays were per-
formed to assess synergy responses with C5a UTP stimulations. E, responses were quantified for synergy ratio using peak offset measurements (1 unit
predicted additive response of each cell). Shown are results from n 3 assays of 2 independently derived cell lines/target. Synergy was reduced by 0.4 units
with RNAi against mPLC3 (*, p 0.05) unless the cells were reconstituted with hPLC3. Error bars, S.E.
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was also restored by mPLC2 although not as robustly as by
hPLC3 (supplemental Fig. S9D). Thus, PLC2, like PLC3,
has the capacity to mediate synergy in these cells.
Both the G and Gq Binding Sites of PLC3 Are Required
for Synergistic Ca2 Responses—PLC3 is responsive to both
G and Gq, and our studies suggest that synergy by Gi
and Gq GPCRs may be mediated by the combined action of
G and Gq on a single PLC isoform. Several alternate
mechanisms have been proposed for synergy between Gi-
and Gq-linked GPCRs in different systems (5), however, and
a direct synergistic activation mechanism does not preclude
contributions from other mechanisms. To examine if the
mechanism of Ca2 synergy for dual C5aR and P2YR stimula-
tion shares a requirement for activation of PLC3 by both
G and Gq, we evaluated the ability of PLC3 mutated in
residues critical for activation by these respective G-proteins
to mediate synergy. Residues in the Y-box of PLC3 homolo-
gous to those critical for the binding of G to PLC1 or resi-
dues in the C terminus homologous to those critical for the
binding of Gq to PLC1 were targeted with X3 Ala muta-
tions (28–31). These sites are depicted in Fig. 1 and described
under “Experimental Procedures” as E262A,T263A,K264A in
the Y-box and K965A,R969A,D1074A,R1089A in the C termi-
nus. Mutation of the Y-box disrupted activation by G in
vitro by80%, but activation by Gq remained intact (Table
1). Mutation of the C terminus diminished activation by Gq
by65%, whereas activation by G was largely intact. Thus,
the functional defects of these mutants were relatively
selective.
We transfected NIH-3T3 cells with the different YFP-
hPLC3 mutants or with a double mutant in which both sites
were targeted. Expression of PLC3 mutated in the Y-box
failed to reconstitute synergy lost by knockdown of endoge-
nous mPLC3 (Fig. 8), indicating a requirement for G acti-
vation of PLC for synergy. In contrast, reconstitution with
WT hPLC3 actually enhanced synergy in these experiments,
suggesting that greater activity exists for this construct, per-
haps due to YFP fusion or human versusmouse sequence ef-
fects. Such an enhancement was suggested, but not statisti-
cally significant, in Fig. 7E. Expression of PLC3 mutated in
the C-terminal domain only partially restored synergy (Fig. 8)
because synergy remained at base-line levels and did not show
the enhancement seen with WT PLC3. The C-terminal mu-
tant appeared50% as effective as intact hPLC3 (supple-
mental Fig. S9C). This partial effect is consistent with the in-
complete effect of the mutation in disrupting Gq activation
(Table 1). Disruption of both Y-box and C-terminal sites dis-
rupted synergy comparable with the Y-box alone. Thus, both
Y-box and C-terminal sites in PLC3 contribute to synergistic
Ca2 responses, supporting the premise that synergy in intact
cells depends on activation of PLC3 by both G and Gq.
These data support a mechanism of Ca2 synergy resulting
from the synergistic activation of PLC3 by the combined
activity of G and Gq released by Gi- and Gq-linked
GPCRs.
DISCUSSION
In the current studies, we demonstrate that the synergistic
increases in intracellular Ca2 following simultaneous stimu-
lation of Gi- and Gq-linked GPCRs in cells can be mediated
by PLC3 or PLC2. PLC1 and PLC4 are instead inhibi-
tory. Ca2 synergy depends on binding sites in PLC3 for
both G in the Y-box domain and Gq in the C terminus.
Based on these findings, we present a model of Ca2 synergy
resulting from the direct, synergistic activation of PLC3 by
combined stimulation with G and Gq.
PLC3 is the predominant isoform used for single-ligand
and synergistic Ca2 responses in macrophages (11). Despite
the fact that macrophages have abundant transcripts for
PLC2, PLC2 does not effectively substitute for PLC3
when the latter is absent (11). We now show that PLC2 is
nonetheless required for the low level of residual synergy de-
tected in PLC3-deficient macrophages because macrophages
deficient in both PLC3 and PLC2 demonstrated no synergy
in their Ca2 response to C5a and UDP. Also, we found that
PLC2 could substitute for PLC3 in NIH-3T3 cells (where it
is not normally expressed at detectable levels); either endoge-
nous PLC3 or exogenous PLC2 produced a robust syner-
gistic Ca2 response in these cells. In contrast, PLC4 did not
FIGURE 8. Binding of both G and Gq contributes to the synergistic
activation of PLC. NIH-3T3 cells were stably transfected with YFP or YFP-
tagged PLC constructs including intact hPLC3, C-terminal mutant
(hPLC3	CT), Y-box mutant (hPLC3	YB), and C-terminal mutant
(hPLC3	YB	CT). Cells were then subjected to RNAi using murine-specific
anti-PLC3 or LacZ control siRNA. Synergy ratios were calculated for each
cell line and treatment. Shown are results from n 4–14 assays of 2–3 inde-
pendently derived cell lines/target. Although intact hPLC3 slightly ele-
vated synergy with RNAi of endogenous mPLC3, the C-terminal mutant
had a reduced capacity, and the Y-box mutant had no activity. *, p 0.05.
NS, not significant; Error bars, S.E.
TABLE 1
In vitro G-protein activation of purified hPLC3
Activity was measured by hydrolysis of 
3HPIP2 and is expressed as -fold
stimulation over basal activity, which was 103.38 13.19 mol of inositol 1,4,5-
trisphosphate/min/mol of PLC. Values shown are from a representative
experiment of four or more with similar results.
Activation
hPLC3 construct
Intact Y-box mutant C-terminal mutant
-fold -fold -fold
G 7.9 2 6.5
Gq 8.5 9.4 4.4
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mediate synergy in either system. Instead, either PLC4 or
PLC1 isoforms tended to inhibit synergy when they were
overexpressed.
These results may be viewed in light of known features of
the PLC isoforms in their binding to G-protein subunits (re-
viewed in Ref. 27). G has been shown to interact both with
residues in the N-terminal pleckstrin homology domain and
in the Y-box of the PLC catalytic domain (30, 31, 35). Only
PLC3 and PLC2 show high affinity binding and activation
by G, and varied combinations of  and  subunits can dif-
fer in their effectiveness (36–40). In our studies, PLC3 and
PLC2 were the only isoforms able to reconstitute synergy in
cells, and mutation of the Y-box G binding site alone led to
a substantial loss of the synergistic activation of PLC3.
Like G, Gq has at least two potential binding sites on
PLC, one in the C terminus and another in the C2 domain
(28, 41–44). Although Gq can activate all isoforms of PLC,
PLC2 is the least sensitive (45, 46). Mutation of the C termi-
nus of PLC1 can disrupt its activation by Gq but not G
(28, 29). In our studies, homologous mutations of PLC3 also
disrupted Gq activation, but not fully; activation was re-
duced by65%. This reduction in Gq activation of the
hPLC3 mutant in vitro correlated with a50% reduced
magnitude of synergy observed in cells. The residual Gq acti-
vation in the PLC3 C-terminal mutant suggests either that
alternate residues in this area contribute to Gq activation or
that there is a role for the other known Gq-binding site in
the C2 domain. Although our C-terminal mutation of PLC3
did not fully ablate Gq activation, our data indicate a contri-
bution of Gq binding to the C terminus of PLC3 in the syn-
ergy mechanism. A role for Gq in the synergy mechanism
was further suggested by the inability of truncation mutants
of PLC2, which eliminated the C-terminal Gq binding re-
gion (truncation at amino acid 840), to mediate synergy in
3T3 cells (data not shown). Overall, our results demonstrate a
direct role for G in PLC3-mediated synergy via binding in
the Y-box catalytic domain, and they support a role for Gq at
the targeted C-terminal binding site.
The capacity to test the activation of purified PLC3 in
vitro by individual or combined G-protein subunits has
opened the path to exploring mechanisms by which G and
Gq may synergize in activating this PLC isoform. Recent
studies by Philip and Ross (47). demonstrate synergistic acti-
vation of PLC3 by simultaneous G and Gq stimulation
in vitro, in accord with our studies in cells. These studies fur-
ther show that the combined action of G and Gq on
PLC3 enhances conversion of the enzyme to the active state
when both ligands are bound rather than merely enhancing
ligand affinity.
The selective use of PLC isoforms in GPCR Ca2 signal-
ing and synergy may involve mechanisms in addition to their
binding of G-proteins, such as the selective use of different
scaffolding or other interacting proteins (48, 49). PDZ do-
main-containing proteins may be of central importance in the
recruitment of PLCs and other regulators of GPCR-medi-
ated Ca2 signaling (48–50). Although all isoforms of PLC
have a PDZ domain-binding motif (X(S/T)X(V/L)) at the C
terminus, their peptide sequences vary and may thus make
differential use of PDZ domains. In support of this, PLC3
preferentially binds to specific PDZ domain-containing scaf-
folding proteins, including NHERF1, E3KARP, and SHANK2
(48, 49, 51). The selective use of PLC3 in GPCR signaling by
macrophages could relate to the selective expression of such
scaffolding proteins in these cells,6 whereas synergy in NIH-
3T3 cells may involve scaffolding proteins that are recognized
more equivalently by both PLC3 and PLC2. Further exami-
nation of PLC3 and PLC2 structural requirements for syn-
ergy are necessary to evaluate these contributions.
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